Getting Help > Clinical Trials > New York

Maximizing Treatment Outcome in OCD
New York State Psychiatric Institute, New York City

Principal Investigator: Dr. H. Blair Simpson

Description of Study: This study compares the effectiveness of two proven treatment strategies for OCD patients who are currently on a serotonin reuptake inhibitor (SRI, i.e., clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, or escitalopram) but still have residual symptoms. Participants remain on their current medication and receive either cognitive-behavioral therapy (CBT) consisting of exposure and ritual prevention or an additional medication (risperidone). The goal is to compare these two augmentation strategies, each of which has been found effective in prior studies. All treatment is at no charge. Note: Patients who do not improve after 8.5 weeks of treatment will be offered at no-cost the treatment they did not initially receive (either the CBT or the add-on medication).

Eligibility Criteria:
18-70 years
Genders: both
Key Inclusion Criteria:
- Primary diagnosis of OCD
- Currently on a stable and adequate dose of an SRI

Exclusion Criteria:
- Medical or psychiatric conditions that would make participation in the study unsafe
- Patients who have already had an adequate trial of these augmentation strategies while on a serotonin reuptake inhibitor

Contact: To schedule a confidential screening, contact Jose Hernandez at 212-543-5367 or Jessica McCarthy at 212-543-5380